(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.30%) $79.19
(0.15%) $2.04
(0.11%) $2 312.20
(0.26%) $26.90
(0.05%) $963.10
(-0.02%) $0.932
(-0.11%) $10.98
(-0.05%) $0.797
(0.00%) $91.13
5 days till quarter result
(bmo 2024-05-07)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Coloplast A/S develops, manufactures, and markets medical products. The company is engaged in the development, marketing and sale of intimate healthcare products and services, targeting people with diseases of private and personal nature...
Stats | |
---|---|
Šios dienos apimtis | 242.00 |
Vidutinė apimtis | 405.00 |
Rinkos kapitalizacija | 25.07B |
EPS | €0 ( 2023-09-30 ) |
Kita pelno data | ( €0 ) 2024-05-07 |
Last Dividend | €5.00 ( 2023-05-15 ) |
Next Dividend | €0 ( N/A ) |
P/E | 37.66 |
ATR14 | €0 (0.00%) |
Coloplast A/S Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Coloplast A/S Finansinės ataskaitos
Annual | 2023 |
Pajamos: | €24.50B |
Bruto pelnas: | €16.33B (66.64 %) |
EPS: | €22.21 |
FY | 2023 |
Pajamos: | €24.50B |
Bruto pelnas: | €16.33B (66.64 %) |
EPS: | €22.21 |
FY | 2022 |
Pajamos: | €22.58B |
Bruto pelnas: | €15.53B (68.78 %) |
EPS: | €22.14 |
FY | 2021 |
Pajamos: | €19.43B |
Bruto pelnas: | €13.31B (68.53 %) |
EPS: | €22.70 |
Financial Reports:
No articles found.
Coloplast A/S Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0 (N/A) |
€15.00 (N/A) |
€0 (N/A) |
€5.00 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €1.800 | 2007-12-19 |
Last Dividend | €5.00 | 2023-05-15 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 27 | -- |
Total Paid Out | €171.20 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.22 | -- |
Div. Sustainability Score | 8.24 | |
Div.Growth Potential Score | 4.74 | |
Div. Directional Score | 6.49 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
NWO.DE | Ex Dividend Knight | 2023-05-25 | Annually | 0 | 0.00% | |
ADS.F | Ex Dividend Junior | 2023-05-12 | Annually | 0 | 0.00% | |
GOB.DE | Ex Dividend Knight | 2023-06-12 | Sporadic | 0 | 0.00% | |
RAA.DE | Ex Dividend Knight | 2023-05-11 | Annually | 0 | 0.00% | |
BLQA.DE | Ex Dividend Knight | 2023-09-07 | Quarterly | 0 | 0.00% | |
INN1.DE | Ex Dividend Junior | 2023-08-07 | Semi-Annually | 0 | 0.00% | |
SYT.DE | Ex Dividend Junior | 2023-05-05 | Annually | 0 | 0.00% | |
CTO.DE | Ex Dividend Knight | 2023-08-24 | Quarterly | 0 | 0.00% | |
LUS1.DE | Ex Dividend Junior | 2023-06-23 | Annually | 0 | 0.00% | |
1U1.DE | Ex Dividend Junior | 2023-05-17 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.194 | 1.500 | 6.11 | 9.17 | [0 - 0.5] |
returnOnAssetsTTM | 0.100 | 1.200 | 6.66 | 7.99 | [0 - 0.3] |
returnOnEquityTTM | 0.429 | 1.500 | 6.35 | 9.52 | [0.1 - 1] |
payoutRatioTTM | 1.175 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 0.532 | 0.800 | -2.34 | -1.871 | [1 - 3] |
quickRatioTTM | 0.281 | 0.800 | -3.06 | -2.44 | [0.8 - 2.5] |
cashRatioTTM | 0.0484 | 1.500 | -0.842 | -1.263 | [0.2 - 2] |
debtRatioTTM | 0.445 | -1.500 | 2.58 | -3.87 | [0 - 0.6] |
interestCoverageTTM | 10.72 | 1.000 | 7.14 | 7.14 | [3 - 30] |
operatingCashFlowPerShareTTM | 27.49 | 2.00 | 0.836 | 1.672 | [0 - 30] |
freeCashFlowPerShareTTM | 21.81 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 1.430 | -1.500 | 4.28 | -6.42 | [0 - 2.5] |
grossProfitMarginTTM | 0.666 | 1.000 | 2.23 | 2.23 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.275 | 1.000 | 6.49 | 6.49 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.278 | 1.000 | 9.57 | 9.57 | [0.2 - 2] |
assetTurnoverTTM | 0.515 | 0.800 | 9.90 | 7.92 | [0.5 - 2] |
Total Score | 8.24 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 38.01 | 1.000 | 6.26 | 0 | [1 - 100] |
returnOnEquityTTM | 0.429 | 2.50 | 7.65 | 9.52 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 21.81 | 2.00 | 2.73 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.48 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 27.49 | 2.00 | 0.836 | 1.672 | [0 - 30] |
payoutRatioTTM | 1.175 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 0.247 | 1.500 | -1.684 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.240 | 1.000 | 6.50 | 0 | [0.1 - 0.5] |
Total Score | 4.74 |
Coloplast A/S
Coloplast A/S develops, manufactures, and markets medical products. The company is engaged in the development, marketing and sale of intimate healthcare products and services, targeting people with diseases of private and personal nature. Its operations are structured into four business areas: Ostomy Care offering products for people whose intestinal outlet has been rerouted through the abdominal wall, Continence Care products for people suffering from diseases of and damage to the urinary system, Urology Care products for people suffering from diseases of and damage to the kidneys, the urinary system or the male reproductive system and Wound & Skin Care for the treatment of chronic wounds and skin care products for prevention and treatment. The firm supplies products to hospitals, institutions as well as wholesalers and pharmacies.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.